Botanicals and Dietary Supplements in Diabetic Peripheral Neuropathy

References

1. ↵
   The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 122: 561–8. 1995;

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 46(Suppl 2): S31–7. 1997;
3. ↵
   McCarty MF. Nitric oxide deficiency, leukocyte activation, and resultant ischemia are crucial to the pathogenesis of diabetic retinopathy/neuropathy—preventive potential of antioxidants, essential fatty acids, chromium, ginkgolides, and pentoxifylline. Med Hypotheses 50: 435–49. 1998;

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   Young MJ, Veves A, Walker MG, Boulton AJ. Correlations between nerve function and tissue oxygenation in diabetic patients: further clues to the aetiology of diabetic neuropathy? Diabetologia 35: 1146–50. 1992;

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   Dietary supplement health and education act of 1994, P.L. 103–417. [103rd Cong, 2nd Sess, Jan 25, 1994.] Washington, DC: Congressional Research Service, Library of Congress, 1994.
6. ↵
   Carter JP. Gamma-linolenic acid as a nutrient. Food Tech 42(6): 72–82. 1988;

   OpenUrl
7. ↵
   Horrobin DF. The regulation of prostaglandin biosynthesis by the manipulation of essential fatty acid metabolism. Rev Pure Appl Pharmacol Sci 4: 339–83. 1983;

   OpenUrlPubMed
8. ↵
   Brenner RR. Nutritional and hormonal factors influencing desaturation of essential fatty acids. Progr Lipid Res 20: 41–8. 1982;

   OpenUrl
9. ↵
   Horrobin DF. A new concept of lifestyle-related cardiovascular disease: the importance of interactions between cholesterol, essential fatty acids, prostaglandin E1 and thromboxane A2. Med Hypotheses 6: 785–800. 1980;

   OpenUrlPubMed
10. ↵
    Horrobin DF. The roles of essential fatty acids in the development of diabetic neuropathy and other complications of diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 31: 181–97. 1988;

    OpenUrlPubMedWeb of Science
11. ↵
    Boberg M, Vessby B, Selinus I. Effects of dietary supplementation with n-6 and n-3 long-chain polyunsaturated fatty acids on serum lipoproteins and platelet function in hypertriglyceridaemic patients. Acta Med Scand 220: 153–60. 1986;

    OpenUrlPubMed
12. ↵
    Takahashi R, Inoue J, Ito H, Hibino H. Evening primrose oil and fish oil in non-insulin-dependent-diabetes. Prostaglandins Leukot Essent Fatty Acids 49: 569–71. 1993;

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    Cameron NE, Cotter MA, Robertson S. Essential fatty acid diet supplementation. Effects on peripheral nerve and skeletal muscle function and capillarization in streptozocin-induced diabetic rats. Diabetes 40: 532–9. 1991;

    OpenUrlAbstract/FREE Full Text
14. ↵
    Jamal GA. The use of gamma linolenic acid in the prevention and treatment of diabetic neuropathy. Diabet Med 11: 145–9. 1994;

    OpenUrlPubMed
15. ↵
    Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabet Med 7: 319–23. 1990;

    OpenUrlPubMedWeb of Science
16. ↵
    Keen H, Payan J, Allawi J, et al. Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care 16: 8–15. 1993;

    OpenUrlAbstract/FREE Full Text
17. ↵
    Purewal TS, Evans PMS, Havard F, O’Hare JP. Lack of effect of evening primrose oil on autonomic function tests after 12 months of treatment. Diabetologia 40(Suppl 1): A556. 1997;

    OpenUrl
18. ↵
    Rosenstock J. Treatment strategies and new therapeutic advances for type 2 diabetes. Diabetes Educ 26:(Suppl): 14–8. 2000;
19. ↵
    Vaddadi KS. The use of gamma-linolenic acid and linoleic acid to differentiate between temporal lobe epilepsy and schizophrenia. Prostaglandins Med 6: 375–9. 1981;

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    Shuster J. Herbal remedies and seizures. Nursing 27(4): 75. 1997;

    OpenUrlPubMed
21. ↵
    Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 19: 227–50. 1995;

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18: 1160–7. 1995;

    OpenUrlAbstract/FREE Full Text
23. ↵
    Low PA, Nickander KK, Tritschler HJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 46(Suppl. 2): S38–S42. 1997;
24. ↵
    Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 107: 421–30. 1999;

    OpenUrlCrossRefPubMedWeb of Science
25. ↵
    Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid. A three-week multicentre randomized controlled trial (ALADIN study). Diabetologia 38: 1425–33. 1995;

    OpenUrlCrossRefPubMedWeb of Science
26. ↵
    Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with antioxidant thioctic acid (α-lipoic acid): a two-year multi-center randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 31: 171–9. 1999;

    OpenUrlPubMedWeb of Science
27. ↵
    Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 22: 1296–301. 1999;

    OpenUrlAbstract
28. ↵
    Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 16: 1040–3. 1999;

    OpenUrlCrossRefPubMedWeb of Science
29. ↵
    Young MJ, Boulton AJ, MacLead AF, Williams DR, Sonksen, PH. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 36: 150–4. 1993;

    OpenUrlCrossRefPubMedWeb of Science
30. ↵
    Zhang WY, Po LW. The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol 46: 517–22. 1994;

    OpenUrlPubMedWeb of Science
31. ↵
    Robbins WR. Clinical applications of capsaicinoids. Clin J Pain 16(2 Suppl): S86–9. 2000;

    OpenUrlCrossRefPubMed
32. ↵
    Scheffler NM, Sheitel PL, Lipton MN. Treatment of painful diabetic neuropathy with capsaicin 0.075%. J Am Podiatr Med Assoc 81(6): 288–93. 1991;

    OpenUrlPubMedWeb of Science
33. ↵
    Markovits E, Gilhar A. Capsaicin—an effective topical treatment in pain. Int J Dermatol 36: 401–4. 1997;

    OpenUrlPubMedWeb of Science
34. ↵
    Tandan R, Lewis GA, Badger GB, Fries TJ. Topical capsaicin in painful diabetic neuropathy. Effect on sensory function. Diabetes Care 15: 15–8. 1992;

    OpenUrlAbstract/FREE Full Text
35. ↵
    Biesbroeck R, Bril V, Hollander P, et al. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther 12: 111–20. 1995;

    OpenUrlPubMedWeb of Science
36. ↵
    Chad DA, Aronin N, Lundstrom R, et al. Does capsaicin relieve the pain of diabetic neuropathy? Pain 42: 387–8. 1990;

    OpenUrlCrossRefPubMedWeb of Science
37. ↵
    Treatment of painful diabetic neuropathy with topical capsaicin—a multicentre, double-blind, vehicle-controlled study. The Capsaicin Study Group. Arch Intern Med 151: 2225–9. 1991;

    OpenUrlCrossRefPubMedWeb of Science
38. ↵
    Tandan R, Lewis GA, Krusinski PB, Badger GB, Fries TJ. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care 15: 8–14. 1992;

    OpenUrlAbstract/FREE Full Text
39. ↵
    Low PA, Opfer-Gehrking TL, Dyck PJ, Litchy WJ, O’Brien PC. Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Pain 62: 163–8. 1995;

    OpenUrlCrossRefPubMedWeb of Science
40. ↵
    Quatraro A, Roca P, Donzella C, Acampora R, Marfella R, Giugliano D. Acetyl-𝓁-carnitine for symptomatic diabetic neuropathy. Diabetologia 38: 123. 1995;

    OpenUrlPubMed
41. ↵
    Stevens M, Lattimer SA, Feldman E. Protective effects of acetyl-𝓁-carnitine on ketogenesis and sciatic nerve function in the streptozotocin diabetic rat. Diabetes 43(Suppl 1): 17A. 1994;

    OpenUrl
42. Merry AC, Kamijo M, Lattimer SA, Ristic H, Sima AA. Long-term prevention and intervention effects of acetyl-𝓁-carnitine on diabetic neuropathy. Diabetes 43(Suppl. 1): 108A. 1994;

    OpenUrl
43. Lowitt S, Malone JI, Salem AF, Korthals J, Benford S. Acetyl-𝓁-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism 44: 677–80. 1995;

    OpenUrlCrossRefPubMedWeb of Science
44. ↵
    Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJM, ALCAR Foot Ulcer Study Group. Effect of treatment with acetyl-L-carnitine on diabetic foot ulceration in patients with peripheral neuropathy: a 1 year prospective multi-centre study. Diabetologia 40(Suppl. 1): A556. 1997;
45. ↵
    McCann YJ, Davis RE. Serum pyridoxal concentrations in patients with diabetic neuropathy. Aust NZ J Med 8: 259–61. 1978;

    OpenUrlPubMed
46. ↵
    Carlson HB, Anthony EM, Russell WF, Middlebrook G. Prophylaxis of isoniazid neuropathy with pyridoxine. N Engl J Med 255: 188. 1956;
47. ↵
    Jones CL, Gonzalez V. Pyridoxine deficiency: a new factor in diabetic neuropathy. J Am Podiatry Assoc 68: 646–53. 1978;

    OpenUrlPubMed
48. ↵
    Cohen KL, Gorecki GA, Silverstein SB, Ebersole JS, Solomon LR. Effect of pyridoxine (vitamin B6) on diabetic patients with peripheral neuropathy. J Am Podiatry Assoc 74: 394–7. 1984;

    OpenUrlPubMed
49. Levin ER, Hanscom TA, Fisher M, et al. The influence of pyridoxine in diabetic peripheral neuropathy. Diabetes Care 4: 606–9. 1981;

    OpenUrlAbstract/FREE Full Text
50. McCann VJ, Davis RE. Pyridoxine and diabetic neuropathy: a double-blind controlled study. Diabetes Care 6: 102–3. 1983;

    OpenUrl
51. ↵
    Tutuncu NB, Bayraktar M, Varli K. Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study. Diabetes Care 11: 1915–8. 1998;

    OpenUrl
52. ↵
    Sindrup SH, Madsen C, Bach FW, Gram LF, Jensen TS. St. John’s wort has no effect on pain in polyneuropathy. Pain 91: 361–5. 2001;

    OpenUrlPubMedWeb of Science